Equities

Aurobindo Pharma Ltd

AUROPHARMA:NSI

Aurobindo Pharma Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (INR)1,528.10
  • Today's Change-7.90 / -0.51%
  • Shares traded692.59k
  • 1 Year change+70.80%
  • Beta0.8892
Data delayed at least 15 minutes, as of Sep 19 2024 11:17 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of INR
(except for per share items)
Fiscal data as of Mar 31 2024202420232022
ASSETS
Cash And Short Term Investments63,26462,32745,576
Total Receivables, Net76,25866,87158,830
Total Inventory98,08285,11275,539
Prepaid expenses------
Other current assets, total4,4521,1461,283
Total current assets242,056215,457181,227
Property, plant & equipment, net142,849124,918106,660
Goodwill, net5,9525,9614,754
Intangibles, net34,81533,25931,379
Long term investments3,2173,9176,183
Note receivable - long term8,1647,0654,839
Other long term assets1,5141,4131,203
Total assets450,715398,900339,217
LIABILITIES
Accounts payable44,54238,71327,031
Accrued expenses3,4632,0761,626
Notes payable/short-term debt40,78141,64721,178
Current portion long-term debt/capital leases1,8211,8103,255
Other current liabilities, total31,38530,69128,470
Total current liabilities121,991114,93881,560
Total long term debt23,8749,4055,678
Total debt66,47652,86230,112
Deferred income tax3,5663,8964,110
Minority interest80120(19)
Other liabilities, total2,7762,1432,129
Total liabilities152,287130,50193,457
SHAREHOLDERS EQUITY
Common stock586586586
Additional paid-in capital4,1794,1794,179
Retained earnings (accumulated deficit)278,483249,573234,230
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total15,18014,0616,765
Total equity298,428268,399245,760
Total liabilities & shareholders' equity450,715398,900339,217
Total common shares outstanding586586586
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.